Trial intelligence / Profile preview

CTR20200377

CTR20200377Phase 2Completed

Sponsor
Shanghai Institute of Applied Physics
Start
Apr 2020
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Countries
1
01

Overview

A Phase 2 trial of Rhenium-188-HEDP in prostate cancer (PCa), sponsored by Shanghai Institute of Applied Physics. Started Apr 2020; status: completed.

02

Drugs

Rhenium-188-HEDP
03

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on CTR20200377.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20200377.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call